User:Mr. Ibrahem/Omalizumab

Omalizumab, sold under the brand name Xolair, is a medication used to treat asthma, nasal polyps, and urticaria. It is used when the cause is allergic and other treatments are not sufficient. It is given by injection.

Common side effects include headache, pain at the site of injection, itching, and abdominal pain. Other side effects may include anaphylaxis, cancer, and heart disease. Following use in a small number of pregnant women there is no evidence of harm to the baby. It is a monoclonal antibody which binds to and inactivates immunoglobulin E (IgE).

Omalizumab was approved for medical use in the United States in 2003 and Europe in 2005. In the United Kingdom 150 mg cost the NHS about £260 as of 2021. This amount in the United States costs about 1,200 USD.